is glp 1 a drug New GLP-1 Guidelines for Type 2 Diabetes in 2025 Patients' Use GLP-1 Drugs for

Patients were sorted into 2 cohorts based on whether they had received a prescription for a GLP-1 RA (semaglutide, lixisenatide, tirzepatide, dulaglutide, liraglutide, or exenatide): those with GLP-1 RA prescriptions were considered the treatment group, whereas those without GLP-1 RA prescriptions were considered the control group

is a consultant to Altimmune, Amgen, Kallyope, Merck, Novo Nordisk and Pfizer

12 The crude rate of major birth defects in the GLP1-RA-exposed women was 2.6%, aligning with the prevalence of major birth defects as reported by EUROCAT which was 2.6% including genetic anomalies for the years 20052021

Kumarathurai P, Anholm C, Larsen BS, et al

#IFM2026AIC #IFM #functionalmedicine #SDH #socialdeterminantsofhealth To view or add a comment, sign in -

Market Report Scope Glucagon Like Peptide 1 Analogs Market Report Coverage Uncover macros and micros vetted on 75+ parameters: Get instant access to report Glucagon Like Peptide 1 Analogs Market Dynamics To learn more about this report, Glucagon Like Peptide 1 Analogs Market Driver - Rising Prevalence of Type 2 Diabetes and Obesity The escalating prevalence of type 2 diabetes and obesity worldwide is a significant factor driving the demand for Glucagon Like Peptide 1 (GLP-1) analogs